Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 221-231

  Wachsmann, Jason ^a   Peng, Fangyu ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Copper metabolism; Gene therapy; Hepatocellular carcinoma; Positron emission tomography; Radionuclide therapy; RNA interference

Indexed keywords

BIOLOGICAL MARKER; CHELATING AGENT; COPPER; COPPER 64; COPPER CHELATING AGENT; COPPER TRANSPORTER 1; PROTEIN; RADIOISOTOPE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); COPPER METABOLISM; COPPER TRANSPORT; DRUG TARGETING; HUMAN; ION TRANSPORT; LIVER CELL CARCINOMA; METASTASIS; MOLECULAR IMAGING; MOLECULAR THERAPY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; ANIMAL; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; LIVER NEOPLASMS; METABOLISM; MOUSE; THERANOSTIC NANOMEDICINE;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; COPPER; COPPER RADIOISOTOPES; HUMANS; LIVER NEOPLASMS; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THERANOSTIC NANOMEDICINE;

EID: 84953375767     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.221     Document Type: Article

References (103)

1. Johnson MA, Kays SE. Copper: its role in human nutrition. Nutrition Today 1990; 25: 6 [DOI: 10.1097/00017285-199001000-00003]
2. Danks DM. Copper deficiency in humans. Annu Rev Nutr 1988; 8: 235-257 [PMID: 3060166]
3. Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC, 2000. Available from: URL: http://www.nap.org
4. Price CT, Langford JR, Liporace FA. Essential Nutrients for Bone Health and a Review of their Availability in the Average North American Diet. Open Orthop J 2012; 6: 143-149 [PMID: 22523525 DOI: 10.2174/1874325001206010143]
5. Mason KE. A conspectus of research on copper metabolism and requirements of man. J Nutr 1979; 109: 1979-2066 [PMID: 387922]
6. Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr 1998; 67: 1054S-1060S [PMID: 9587151]
7. Turnlund JR, King JC, Gong B, Keyes WR, Michel MC. A stable isotope study of copper absorption in young men: effect of phytate and alpha-cellulose. Am J Clin Nutr 1985; 42: 18-23 [PMID: 2990188]
8. Turnlund JR, Keyes WR, Anderson HL, Acord LL. Copper absorption and retention in young men at three levels of dietary copper by use of the stable isotope 65Cu. Am J Clin Nutr 1989; 49: 870-878 [PMID: 2718922]
9. Evans GW. Copper homeostasis in the mammalian system. Physiol Rev 1973; 53: 535-570 [PMID: 4354642]
10. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-337 [PMID: 8298639 DOI: 10.1038/ng1293-327]
11. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-350 [PMID: 8298641 DOI: 10.1038/ng1293-344]
12. Cox DW, Prat L, Walshe JM, Heathcote J, Gaffney D. Twentyfour novel mutations in Wilson disease patients of predominantly European ancestry. Hum Mutat 2005; 26: 280 [PMID: 16088907 DOI: 10.1002/humu.9358]
13. Wu J, Forbes JR, Chen HS, Cox DW. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 1994; 7: 541-545 [PMID: 7951327 DOI: 10.1038/ng0894-541]
14. Togashi Y, Li Y, Kang JH, Takeichi N, Fujioka Y, Nagashima K, Kobayashi H. D-penicillamine prevents the development of hepatitis in Long-Evans Cinnamon rats with abnormal copper metabolism. Hepatology 1992; 15: 82-87 [PMID: 1370162 DOI: 10.1002/hep.1840150116]
15. Gollan JL, Davis PS, Deller DJ. Binding of copper by human alimentary secretions. Am J Clin Nutr 1971; 24: 1025-1027 [PMID: 5094476]
16. Gregoriadis G, Sourkes TL. Role of protein in removal of copper from the liver. Nature 1968; 218: 290-291 [PMID: 5648232 DOI: 10.1038/218290a0]
17. Wolters MG, Schreuder HA, van den Heuvel G, van Lonkhuijsen HJ, Hermus RJ, Voragen AG. A continuous in vitro method for estimation of the bioavailability of minerals and trace elements in foods: application to breads varying in phytic acid content. Br J Nutr 1993; 69: 849-861 [PMID: 8329359 DOI: 10.1079/BJN19930085]
18. Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. Am J Clin Nutr 1992; 56: 917-925 [PMID: 1329483]
19. Madari A, Ginter E, Kadrabová J. Serum copper, zinc and copper/zinc ratio in males: influence of aging. Physiol Res 1994; 43: 107-111 [PMID: 7918334]
20. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-And HCV-Associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135 [PMID: 23344543 DOI: 10.1038/nrc3449]
21. Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol 2015; 24: 335-345 [PMID: 25560752 DOI: 10.1016/j.intimp.2014.12.024]
22. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. Oncology 2003; 65: 323-330 [PMID: 14707452 DOI: 10.1159/000074645]
23. Iwadate H, Ohira H, Suzuki T, Abe K, Yokokawa J, Takiguchi J, Rai T, Orikasa H, Irisawa A, Obara K, Kasukawa R, Sato Y. Hepatocellular carcinoma associated with Wilson's disease. Intern Med 2004; 43: 1042-1045 [PMID: 15609699]
24. Xu R, Hajdu CH. Wilson disease and hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2008; 4: 438-439 [PMID: 21904522]
25. Haratake J, Horie A, Takeda S, Kobori K, Sato H, Tokudome S. Tissue copper content in primary and metastatic liver cancers. Acta Pathol Jpn 1987; 37: 231-238 [PMID: 3037846 DOI: 10.1111/j.1440-1827.1987.tb03059.x]
26. Maeda T, Shimada M, Harimoto N, Tsujita E, Maehara S, Rikimaru T, Tanaka S, Shirabe K, Maehara Y. Role of tissue trace elements in liver cancers and non-cancerous liver parenchyma. Hepatogastroenterology 2005; 52: 187-190 [PMID: 15783026]
27. Poo JL, Rosas-Romero R, Montemayor AC, Isoard F, Uribe M. Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study. J Gastroenterol 2003; 38: 45-51 [PMID: 12560921 DOI: 10.1007/s005350300005]
28. Wilkinson ML, Portmann B, Williams R. Wilson's disease and hepatocellular carcinoma: possible protective role of copper. Gut 1983; 24: 767-771 [PMID: 6307837 DOI: 10.1136/gut.24.8.767]
29. Cheng WS, Govindarajan S, Redeker AG. Hepatocellular carcinoma in a case of Wilson's disease. Liver 1992; 12: 42-45 [PMID: 1314321]
30. Honda H, Onitsuka H, Murakami J, Kaneko K, Murayama S, Adachi E, Kanematsu T, Sugimachi K, Masuda K. Characteristic findings of hepatocellular carcinoma: an evaluation with comparative study of US, CT, and MRI. Gastrointest Radiol 1992; 17: 245-249 [PMID: 1319366 DOI: 10.1007/BF01888559]
31. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219: 316-333 [PMID: 11323453 DOI: 10.1148/radiology.219.2.r01 ma19316]
32. Wachsmann JW, Gerbaudo VH. Thorax: normal and benign pathologic patterns in FDG-PET/CT imaging. PET Clin 2014; 9: 147-168 [PMID: 25030279 DOI: 10.1016/j.cpet.2013.10.004]
33. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817 [PMID: 7562048]
34. Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res 2011; 41: 611-617 [PMID: 21711419 DOI: 10.1111/j.1872-034X.2011.00819.x]
35. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-3319 [PMID: 10566736 DOI: 10.1111/j.1572-0241.1999.01544.x]
36. Wang SB, Wu HB, Wang QS, Zhou WL, Tian Y, Li HS, Ji YH, Lv L. Combined early dynamic (18)F-FDG PET/CT and conventional whole-body (18)F-FDG PET/CT provide one-stop imaging for detecting hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2015; 39: 324-330 [PMID: 25487755 DOI: 10.1016/j.clinre.2014.10.010]
37. Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, Cheon GJ, Han JK, Choi BI. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015; 40: 843-851 [PMID: 25253426 DOI: 10.1007/s00261-014-0256-0]
38. Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, Zakher B, Pappas M, Graham E, Sullivan S. Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Oct. Report No.: 14(15)-EHC048-EF [PMID: 25473698]
39. Ho CL, Yu SC, Yeung DW. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-221 [PMID: 12571212]
40. Huo L, Dang Y, Lv J, Xing H, Li F. Application of dual phase imaging of 11C-Acetate positron emission tomography on differential diagnosis of small hepatic lesions. PLoS One 2014; 9: e96517 [PMID: 24816814 DOI: 10.1371/journal.pone.0096517]
41. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, Kaji M, Ohkawa M. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 2008; 49: 1245-1248 [PMID: 18632827 DOI: 10.2967/jnumed.108.052639]
42. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51: 1699-1706 [PMID: 20956466 DOI: 10.2967/jnumed.110.075507]
43. Bush JA, Mahoney JP, Markowitz H, Gubler CJ, Cartwright GE, Wintrobe MM. Studies on copper metabolism. XIV. Radioactive copper studies in normal subjects and in patients with hepatolenticular degeneration. J Clin Invest 1955; 34: 1766-1778 [PMID: 13271562]
44. Osborn SB, Szaz KF, Walshe JM. Studies with radioactive copper (64Cu and 67Cu): abdominal scintiscans in patients with Wilson's disease. Q J Med 1969; 38: 467-474 [PMID: 5355538]
45. Walshe JM, Potter G. The pattern of the whole body distribution of radioactive copper (67Cu, 64Cu) in Wilson's Disease and various control groups. Q J Med 1977; 46: 445-462 [PMID: 413153]
46. Peng F. Positron emission tomography for measurement of copper fluxes in live organisms. Ann N Y Acad Sci 2014; 1314: 24-31 [PMID: 24628290 DOI: 10.1111/nyas.12383]
47. Peng F, Liu J, Wu JS, Lu X, Muzik O. Mouse extrahepatic hepatoma detected on MicroPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol 2005; 7: 325-329 [PMID: 16220354]
48. Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med 2006; 47: 1649-1652 [PMID: 17015901]
49. Zhang H, Cai H, Lu X, Muzik O, Peng F. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol 2011; 18: 1561-1568 [PMID: 22055798 DOI: 10.1016/j.acra.2011.08.006]
50. Peng F, Lutsenko S, Sun X, Muzik O. Positron emission tomography of copper metabolism in the Atp7b-/-knock-out mouse model of Wilson's disease. Mol Imaging Biol 2012; 14: 70-78 [PMID: 21327972 DOI: 10.1007/s11307-011-0476-4]
51. Peng F, Lutsenko S, Sun X, Muzik O. Imaging copper metabolism imbalance in Atp7b (-/-) knockout mouse model of Wilson's disease with PET-CT and orally administered 64CuCl2. Mol Imaging Biol 2012; 14: 600-607 [PMID: 22170165 DOI: 10.1007/s11307-011-0532-0]
52. Jørgensen JT, Persson M, Madsen J, Kjaer A. High tumor uptake of (64)Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol 2013; 40: 345-350 [PMID: 23394821 DOI: 10.1016/j.nucmedbio.2013.01.002]
53. Cai H, Wu JS, Muzik O, Hsieh JT, Lee RJ, Peng F. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med 2014; 55: 622-628 [PMID: 24639459 DOI: 10.2967/jnumed.113.126979]
54. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
55. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S80-S89 [PMID: 25755616 DOI: 10.1016/j.jceh.2014.05.004]
56. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62: 1187-1195 [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010]
57. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 [PMID: 12540794]
58. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481 [PMID: 17239480 DOI: 10.1016/j.jhep.2006.10.020]
59. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-551 [PMID: 19937027 DOI: 10.1007/s00270-009-9750-0]
60. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014; 111: 255-264 [PMID: 24937669 DOI: 10.1038/bjc.2014.199]
61. Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19: 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515]
62. Kumar M, Panda D. Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S130-S139 [PMID: 25755605 DOI: 10.1016/j.jceh.2014.03.049]
63. Nasulewicz A, Mazur A, Opolski A. Role of copper in tumour angiogenesis-clinical implications. J Trace Elem Med Biol 2004; 18: 1-8 [PMID: 15487757 DOI: 10.1016/j.jtemb.2004.02.004]
64. Soncin F, Guitton JD, Cartwright T, Badet J. Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 1997; 236: 604-610 [PMID: 9245697 DOI: 10.1006/bbrc.1997.7018]
65. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptidecopper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci 2000; 67: 2257-2265 [PMID: 11045606 DOI: 10.1016/S0024-3205(00)00803-1]
66. Engleka KA, Maciag T. Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation. J Biol Chem 1992; 267: 11307-11315 [PMID: 1375939]
67. Moriguchi M, Nakajima T, Kimura H, Watanabe T, Takashima H, Mitsumoto Y, Katagishi T, Okanoue T, Kagawa K. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 2002; 102: 445-452 [PMID: 12432545 DOI: 10.1002/ijc.10740]
68. Brem S, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 1990; 26: 391-396 [PMID: 2320207 DOI: 10.1227/00006123-199003000-00003]
69. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000; 6: 1-10 [PMID: 10656425]
70. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-194 [PMID: 1673721]
71. Hasan NM, Lutsenko S. Regulation of copper transporters in human cells. Curr Top Membr 2012; 69: 137-161 [PMID: 23046650 DOI: 10.1016/B978-0-12-394390-3.00006-9]
72. Turski ML, Thiele DJ. New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem 2009; 284: 717-721 [PMID: 18757361 DOI: 10.1074/jbc.R800055200]
73. Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci USA 2013; 110: 19507-19512 [PMID: 24218578 DOI: 10.1073/pnas.1318431110]
74. Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, Counter CM. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 2014; 509: 492-496 [PMID: 24717435 DOI: 10.1038/nature13180]
75. Grubman A, White AR. Copper as a key regulator of cell signalling pathways. Expert Rev Mol Med 2014; 16: e11 [PMID: 24849048 DOI: 10.1017/erm.2014.11]
76. Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res 2014; 74: 5819-5831 [PMID: 25320179 DOI: 10.1158/0008-5472.CAN-13-3527]
77. Zhou B, Gitschier J. hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 1997; 94: 7481-7486 [PMID: 9207117]
78. Sharma H. Role of external beam radiation therapy in management of hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S122-S125 [PMID: 25755603 DOI: 10.1016/j.jceh.2014.05.002]
79. Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A, Cattral MS, McGilvray ID, Levy GA, Renner E, Greig PD, Grant DR. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010; 23: 299-306 [PMID: 19843294 DOI: 10.1111/j.1432-2277.2009.00980.x]
80. Jiang W, Zeng ZC, Zhang JY, Fan J, Zeng MS, Zhou J. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis 2012; 29: 197-205 [PMID: 22173728 DOI: 10.1007/s10585-011-9442-4]
81. Kodama H, Aikata H, Uka K, Takaki S, Mori N, Waki K, Jeong SC, Kawakami Y, Shirakawa H, Takahashi S, Toyota N, Ito K, Chayama K. Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma. Oncology 2007; 72: 285-292 [PMID: 18187950 DOI: 10.1159/000113040]
82. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med 2003; 44: 1945-1961 [PMID: 14660721]
83. Sundram F. Radionuclide therapy of hepatocellular carcinoma. Biomed Imaging Interv J 2006; 2: e40 [PMID: 21614248 DOI: 10.2349/biij.2.3.e40]
84. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81 [PMID: 18027884 DOI: 10.1002/hep.21980]
85. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: 335-345 [PMID: 15064336 DOI: 10.1097/01. RVI.0000123319.20705.92]
86. Keng GH, Sundram FX, Yu SW, Somanesan S, Premaraj J, Oon CJ, Kwok R, Htoo MM. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-Arterial radio-conjugates. Ann Acad Med Singapore 2002; 31: 382-386 [PMID: 12061301]
87. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15: 214-223 [PMID: 17989705]
88. Jin YN, Chung HK, Kang JH, Lee YJ, Kimm KI, Kim YJ, Kim S, Chung JK. Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein. Cancer Biother Radiopharm 2008; 23: 551-560 [PMID: 18986218 DOI: 10.1089/cbr.2008.0467]
89. Ma XJ, Huang R, Kuang AR. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest 2009; 27: 673-681 [PMID: 19241193 DOI: 10.1080/07357900802620885]
90. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957-980 [PMID: 9004284 DOI: 10.1016/S0969-8051(96)00130-8]
91. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol 2004; 386: 237-261 [PMID: 15120255]
92. Evangelista L, Luigi M, Cascini GL. New issues for copper-64: from precursor to innovative PET tracers in clinical oncology. Curr Radiopharm 2013; 6: 117-123 [PMID: 23886447]
93. Niccoli Asabella A, Cascini GL, Altini C, Paparella D, Notaristefano A, Rubini G. The copper radioisotopes: a systematic review with special interest to 64Cu. Biomed Res Int 2014; 2014: 786463 [PMID: 24895611 DOI: 10.1155/2014/786463]
94. Apelgot S, Coppey J, Gaudemer A, Grisvard J, Guille E, Sasaki I, Sissoeff I. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol 1989; 55: 365-384 [PMID: 2564034 DOI: 10.1080/09553008914550421]
95. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003; 44: 1284-1292 [PMID: 12902420]
96. Chong HS, Mhaske S, Lin M, Bhuniya S, Song HA, Brechbiel MW, Sun X. Novel synthetic ligands for targeted PET imaging and radiotherapy of copper. Bioorg Med Chem Lett 2007; 17: 6107-6110 [PMID: 17911020]
97. Yuan J, You Y, Lu X, Muzik O, Oupicky D, Peng F. Synthesis of Poly[APMA]-DOTA-64Cu conjugates for interventional radionuclide therapy of prostate cancer: assessment of intratumoral retention by micro-positron emission tomography. Mol Imaging 2007; 6: 10-17 [PMID: 17311761]
98. Jin ZH, Furukawa T, Claron M, Boturyn D, Coll JL, Fukumura T, Fujibayashi Y, Dumy P, Saga T. Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4. Angiogenesis 2012; 15: 569-580 [PMID: 22644563 DOI: 10.1007/s10456-012-9281-1]
99. Yuan J, Zhang H, Kaur H, Oupicky D, Peng F. Synthesis and characterization of theranostic poly(HPMA)-c(RGDyK)-DOTA-64Cu copolymer targeting tumor angiogenesis: tumor localization visualized by positron emission tomography. Mol Imaging 2013; 12: 203-212 [PMID: 23490439]
100. Sparks R, Peng F. Positron emission tomography of altered copper metabolism for metabolic imaging and personalized therapy of prostate cancer. J Radiol Radiat Ther 2013; 1: 1015
101. Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med 2015; 29: 482-488 [PMID: 25833290]
102. Qin C, Liu H, Chen K, Hu X, Ma X, Lan X, Zhang Y, Cheng Z. Theranostics of malignant melanoma with 64CuCl2. J Nucl Med 2014; 55: 812-817 [PMID: 24627435 DOI: 10.2967/jnumed.113.133850]
103. Kim KI, Jang SJ, Park JH, Lee YJ, Lee TS, Woo KS, Park H, Choe JG, An GI, Kang JH. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model. J Nucl Med 2014; 55: 1692-1698 [PMID: 25091475 DOI: 10.2967/jnumed.114.141127]